Table 7. Quality and Risk of Bias Assessment Using the Quality In Prognosis Studies (QUIPS) Tool[1]

A. Included Studies in Cross-sectional Data Analysis

Study (First author, year)	Study Participation	Study Attrition	Outcome Measurement	Study Confounding	Statistical Analysis and Reporting
Dimopoulos et al, 2018[2]	Low risk	Low risk	Low risk	Moderate risk	Low risk
Dysli et al, 2016[3]	Moderate risk	Low risk	Low risk	Low risk	Low risk
Fischer et al, 2018[4]	Moderate risk	Low risk	Low risk	Low risk	Low risk
Jain et al, 2016[5]	Moderate risk	Low risk	Low risk	Low risk	Low risk
Jolly et al, 2016[6]	Low risk	Low risk	Low risk	Low risk	Low risk
Seitz et al, 2015[7]	Low risk	Low risk	Low risk	Moderate risk	Low risk

B. Included Studies in Longitudinal Data Analysis

Study (First author, year)	Study Participation	Study Attrition	Outcome Measurement	Study Confounding	Statistical Analysis and Reporting
Aylward et al, 2018[8]	Low risk	Low risk	Low risk	Low risk	Low risk
Dimopoulos et al, 2018[9]	Moderate risk	Low risk	Low risk	Low risk	Low risk
Fischer et al, 2018[4]	Moderate risk	Low risk	Low risk	Low risk	Low risk
Xue et al, 2018[10]	Low risk	Low risk	Low risk	Low risk	Low risk
Seitz et al, 2015[7]	Low risk	Low risk	Low risk	Moderate risk	Low risk

THOR = Tübingen Choroideremia Gene Therapy Trial.

References:

1. Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158(4):280-6.
2. Dimopoulos IS, Freund PR, Knowles JA, MacDonald IM. The natural history of full-field stimulus threshold decline in choroideremia. Retina 2018;38(9):1731-42.
3. Dysli C, Wolf S, Tran HV, Zinkernagel MS. Autofluorescence lifetimes in patients with choroideremia identify photoreceptors in areas with retinal pigment epithelium atrophy. Invest Ophthalmol Vis Sci 2016;57(15):6714-21.
4. Fischer MD, Ochakovski GA, Beier B, et al. Changes in retinal sensitivity after gene therapy in choroideremia. Retina 2018.
5. Jain N, Jia Y, Gao SS, et al. Optical coherence tomography angiography in choroideremia: correlating choriocapillaris loss with overlying degeneration. JAMA Ophthalmol 2016;134(6):697-702.
6. Jolly JK, Edwards TL, Moules J, et al. A qualitative and quantitative assessment of fundus autofluorescence patterns in patients with choroideremia. Invest Ophthalmol Vis Sci 2016;57(10):4498-503.
7. Seitz IP, Zhour A, Kohl S, et al. Multimodal assessment of choroideremia patients defines pre-treatment characteristics. Graefes Arch Clin Exp Ophthalmol 2015;253(12):2143-50.
8. Aylward JW, Xue K, Patricio MI, et al. Retinal degeneration in choroideremia follows an exponential decay function. Ophthalmology 2018;125(7):1122-4.
9. Dimopoulos IS, Hoang SC, Radziwon A, et al. Two-year results after aav2-mediated gene therapy for choroideremia: the alberta experience. Am J Ophthalmol 2018;193:130-42.
10. Xue K, Jolly JK, Barnard AR, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med 2018;24(10):1507-12.